First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
Subscribe To Our Newsletter & Stay Updated
